Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.
Сравнительное исследованиеСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Plaquevent Marthe, Tétart Florence, Fardet Laurence, Ingen-Housz-Oro Saskia, Valeyrie-Allanore Laurence, Bernard Philippe, Hebert Vivien, Roussel Aude, Avenel-Audran Martine, Chaby Guillaume, D'Incan Michel, Ferrier-Le-Bouedec Marie-Christine, Duvert-Lehembre Sophie, Picard-Dahan Catherine, Jeudy Geraldine, Collet Evelyne, Labeille Bruno, Morice Cécile, Richard Marie-Aleth, Bourgault-Villada Isabelle, Litrowski Noémie, Bara Corina, Mahe Emmanuel, Prost-Squarcioni Catherine, Alexandre Marina, Quereux Gaelle, Bernier Claire, Soria Angèle, Thomas-Beaulieu Domitille, Pauwels Christine, Dereure Olivier, Benichou Jacques, Joly Pascal, French Investigators for Skin Adverse Reaction to Drugs, French Study Group on Autoimmune Bullous Skin Diseases
Аннотация
Dipeptidyl peptidase-4 inhibitors have been suspected to induce bullous pemphigoid (BP). The objective of this study was to compare the observed frequency of gliptin intake in a large sample of 1,787 BP patients diagnosed between 2012 and 2015 in France, with the expected frequency after indirect age standardization on 225,412 individuals extracted from the database of the National Healthcare Insurance Agency. The secondary objective was to assess the clinical characteristics and the course of gliptin-associated BP, depending on whether gliptin was continued or stopped. The observed frequencies of intake of the whole gliptin class and that of vildagliptin in the BP population were higher than those in the general population after age standardization (whole gliptin class: 6.0%; 95% confidence interval = 4.9-7.1% vs. 3.6%, observed-to-expected drug intake ratio = 1.7; 95% confidence interval = 1.4-2.0; P < 0.0001; vildagliptin = 3.3%; 95% confidence interval = 2.5-4.1% vs. 0.7%, ratio = 4.4; 95% confidence interval = 3.5-5.7; P < 0.0001). The association of any gliptin+metformin was also higher than in the general population, ratio = 1.8 (95% confidence interval = 1.3-2.4; P < 0.0001). Gliptin-associated BP had no specific clinical characteristics. Gliptin was stopped in 48 (45.3%) cases. Median duration to achieve disease control, rate, and delay of relapse were not different whether gliptin was stopped or continued. This study strongly supports the association between gliptin intake, particularly vildagliptin, and the onset of BP.